Meet us in Philadelphia, PA at the
Pennsylvania Convention Center

Why CPHI North America Matters

CPHI North America brings together pharmaceutical companies, CDMOs, and industry leaders across North America advancing drug development and manufacturing from early discovery through commercialization. The conference focuses on the chemistry, process development, manufacturing, and supply chain strategies required to deliver small molecule and complex therapeutics efficiently and reliably.

Adesis is a U.S.-based CDMO specializing in small-molecule organic synthesis, supporting pharmaceutical companies from gram-scale discovery through process development and commercial supply. With expanded manufacturing capabilities in Ireland, we provide flexible, high-quality solutions across the full development lifecycle. We attend CPHI North America to connect with pharmaceutical teams and discuss how we can support their development and manufacturing challenges.

Learn more about the event at https://www.cphi.com/americas/.

Meet the Adesis Team at CPHI North America

Our team will be onsite throughout CPHI North America to meet with pharmaceutical and biotechnology companies developing small molecule and complex therapeutic programs.

If you’re exploring partners for:

Heterocycles and regulatory starting materials (RSMs)

Linear and cyclic peptides or oligonucleotides

Deuterated drug products

Small molecule linkers for PROTACs, ADCs, and other modalities

Process chemistry, scale-up, and commercial manufacturing

we would welcome the opportunity to connect.

What We Do

Who We Are

Adesis is a U.S.-based contract development and manufacturing organization (CDMO) focused on complex small-molecule and peptide chemistry. We partner with pharmaceutical and biotechnology companies to advance programs from early discovery through specialty manufacturing with precision, speed, and reliability.

With more than 100,000 square feet of laboratory and manufacturing space across two Delaware sites, supported by additional manufacturing capacity in Ireland, and a scientific team comprised of over 100 chemists (approximately 80% PhD-level), Adesis operates as a seamless extension of client R&D organizations—bringing deep technical expertise across small molecules and peptides, rigorous quality systems, and practical execution to every program.

Accelerate

Your Success

Learn More About Adesis

Let's Stay Connected

Beyond the Conference

Follow Us